The stock will be driven by upcoming clinical data readouts (PIVOT-006 topline this month, 12-month data in December) and BLA completion timing. Monitor these catalysts for potential inflection; the widening cash burn and EPS miss are already priced into the pre-revenue stage.
Drug in focus
CGON drug pipeline →cretostimogene
▲ Bullish Named in this 8-K- Impact
- Phase
- Phase 3
- Time to market
- BLA submission planned for Q4 2026 in BCG-unresponsive NMIBC. If accepted and approved under standard FDA review, potential approval could come in H2 2027. The drug already has Breakthrough Therapy designation from the FDA.
- Next catalyst
- None dated
What to watchWatch for BLA submission completion in Q4 2026, this is the key catalyst that will determine whether cretostimogene becomes the first FDA-approved oncolytic virus therapy for NMIBC. Also monitor PIVOT-006 Phase 3 topline data (intermediate-risk NMIBC), which could be imminent. The $1.05B ATM facility creates ongoing dilution overhang, so positive regulatory catalysts are needed to offset that pressure.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 6 $75.99entry
- T+1 · 8d ago −1.65%α −4.01% · $74.74
- T+5 · 4d ago −2.09%α −4.69% · $74.40
- T+6 · todayOpen
- T+20 · in 20d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
CG Oncology reported Q3 2026 net loss of $56.9M ($0.64 per share), wider than the $43.8M loss a year ago, and total revenue of $1.6M. The company reiterated its near-term catalysts: PIVOT-006 Phase 3 topline data expected November 2026, 12-month data from two trials in December, and BLA completion for BCG-unresponsive NMIBC in Q4 2026. Cash of $984.5M is sufficient through 2029. The EPS miss versus consensus and widening losses are the headline financial facts.
Key Financial Metrics
Key Facts
- Q3 2026 net loss of $56.9M, or $0.64 per share, compared to a net loss of $43.8M, or $0.57 per share, in Q3 2025
- Total revenue of $1.6M in Q3 2026, flat versus $1.7M in Q3 2025
- Cash, cash equivalents, and marketable securities of $984.5M as of September 30, 2026, down from $1.0B as of June 30, 2026
- R&D expenses rose to $39.2M from $27.9M year-over-year, driven by clinical trial and CMC costs
- PIVOT-006 Phase 3 topline data expected in November 2026; BLA completion for BCG-unresponsive NMIBC expected Q4 2026
- Appointed Isabel Kalofonos as Chief Commercial Officer in October 2026
Financial Impact
Net loss widened by $13.1M YoY; EPS of $0.64 missed consensus of $0.81 by 21%
Risk Factors
- PIVOT-006 topline data may fail to meet efficacy endpoints
- BLA submission or FDA review could be delayed beyond Q4 2026 guidance
- Cash burn rate may require future capital raises before reaching profitability
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001991792-26-000011 |
| Document: cgon-20261106.htm | 0001991792-26-000011 |
| Document: 0001991792-26-000011-index-headers.html | 0001991792-26-000011 |
| Document: 0001991792-26-000011-index.html | 0001991792-26-000011 |
| Document: 0001991792-26-000011.txt | 0001991792-26-000011 |
| 8-K Data (Synthetic) | 0001991792-26-000011 |
Track record
25 reports on CGON
6 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +26.33% at T+20 after the Jun 12, 2026 report. 7 of 7 went positive at some point.
Filters
- Nov 16, 2026today 8-K Bullish 7/10 Entry $98.84 Now $84.78 −14.23% settles Dec 15
- Nov 16, 2026today Press Release Bullish 7/10 Entry $95.01 Now $84.78 −10.77% settles Dec 15
- Nov 6, 202610d ago 8-K Bearish 5/10 Viewing Entry $75.99 Now $84.78 −11.57% settles Dec 7
- Nov 6, 202610d ago Press Release Neutral 4/10 Entry $75.99 Now $84.78 +11.57% settles Dec 7
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $64.06 Now $84.78 +32.34% settles Dec 2
- Oct 19, 202628d ago 3 Neutral 2/10 Entry $61.93 Now $84.78 +36.90% settles Nov 17
- Oct 15, 20264w ago 144 Neutral 2/10 Entry $59.85 to $74.40 Now $84.78 +41.65% ▲ +24.31% +25.47% vs SPY
- Oct 12, 20265w ago Institutional Cluster Mixed 3/10 Entry $63.13 to $74.74 Now $84.78 +34.29% ▲ +18.39% +21.66% vs SPY
- Aug 6, 202614w ago Press Release Bearish 7/10 Entry $74.85 to $74.33 Now $84.78 −13.27% ▲ +0.69% +1.29% vs SPY
- Aug 6, 202614w ago 424B5 Bearish 6/10 Entry $74.85 to $74.33 Now $84.78 −13.27% ▲ +0.69% +1.29% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers